The short answer: the two results are not contradictory
No. Normal liver enzymes do not mean that the fatty-liver report is wrong or that fibrosis is certainly absent. Ultrasound and blood tests look at different things. Routine ultrasound may detect an appearance consistent with fat accumulation, while enzymes such as ALT and AST reflect substances released from liver cells during injury. Fat may be present without a clear enzyme rise at the time of testing, and some people can have clinically important fibrosis even when their enzymes sit inside the laboratory's printed range. NICE therefore explicitly advises against using routine liver blood tests alone to rule out fatty liver or assess advanced fibrosis [1, 2].
The reassuring part is that a normal result shows no current enzyme elevation, which is genuinely useful information. It is not, however, a complete certificate of liver health and cannot by itself identify the cause of the fatty appearance or the amount of scarring. Current guidance recommends that an incidental fatty-liver finding should prompt consideration of its likely cause and an assessment of fibrosis risk, especially in the presence of type 2 diabetes, central adiposity, raised blood pressure or abnormal blood lipids. The practical message is balanced: do not panic about the word “fatty,” but do not let the word “normal” close the assessment; read both findings alongside medical history, examination and the rest of the results [2, 3].
What do normal enzymes say, and what do they not say?
ALT and AST are commonly called “liver enzymes,” but they are not direct measures of every liver function. They may rise when liver cells are injured, while a value inside the reference interval means that an elevation was not detected in that sample. Interpretation is also influenced by the laboratory's range, timing, age, medicines and a recent acute illness. A clinician therefore considers the actual value and its trend, not only the flags “normal” or “high.” They also distinguish injury enzymes from other measures such as bilirubin, albumin, clotting results and platelets, because each answers a different question [2, 9].
Fatty liver is often silent, and many people have no clear symptoms even when structured follow-up is worthwhile. Tiredness or vague discomfort in the upper right abdomen can occur, but neither is specific to fatty liver or a measure of severity. Similarly, having no pain does not prove that fibrosis is absent. When tests are repeated, useful comparison requires the dates, actual values and clinical circumstances, rather than self-interpreting a small fluctuation. A clinician may repeat selected tests or request other markers according to the history, but does not necessarily need to repeat everything because of anxiety alone. The aim is for each test to answer a defined question instead of chasing one isolated number [5, 6, 9].
Ultrasound saw fat, but where are its limits?
Routine ultrasound uses sound to create an image and may describe the liver as brighter or its appearance as consistent with fat accumulation. It is common and useful, but it cannot establish active steatohepatitis, cannot stage fibrosis accurately, and is less sensitive when the amount of fat is mild. Image quality can also be influenced by body habitus, equipment and operator factors. A word such as “mild” or a “grade” in the report should not therefore be converted into a prediction about the future, and repeating ultrasound quickly will not necessarily answer the missing question [4, 5].
The report should be read with the reason for the scan, images when available and earlier results. The clinician also reviews whether another cause of liver fat may apply, such as the relevant pattern of alcohol use, a medicine, rapid weight loss, malnutrition or a less common condition. This does not mean that everyone needs an enormous test panel; selection is tailored to the history and risk factors. If you want to understand the report wording without drifting into the separate subjects of fibrosis and treatment, see the fatty-liver ultrasound guide, which explains the role and limits of imaging and the practical steps after a result [3, 5, 6].
The key question: does fibrosis risk need another step?
Fibrosis means scarring; it is different from liver fat and from an enzyme elevation. A clinician often starts with a simple assessment that combines age, AST, ALT and platelet count in a score such as FIB-4. The score is not a diagnosis, and entering your numbers into a website should not become a treatment decision. Its performance and limitations vary with age, pregnancy, acute illness and some accompanying conditions. Its main value is helping separate a low likelihood that may suit structured follow-up from an indeterminate or higher result that warrants review or another test [2, 4].
If the question remains open, the clinician may select liver-stiffness measurement with elastography or another non-invasive method. Stiffness is not automatically synonymous with fibrosis because inflammation, congestion and measurement quality can influence it, so its result also needs context. Biopsy is not routine for everyone with fatty liver; it has a selected role when non-invasive tests do not settle an important question or another disease remains possible. The liver-fibrosis assessment guide explains the difference between fat and scarring without repeating the treatment topic. The central point here is that a normal enzyme result does not cancel a fibrosis pathway when the person's risk profile makes one appropriate [1, 2, 3, 5].
What does the clinician review beyond the liver?
The current term MASLD links steatotic liver disease with one or more cardiometabolic factors, such as altered glucose or insulin resistance, increased waist size, raised blood pressure or abnormal blood lipids. A risk factor does not prove fibrosis, and the absence of excess weight does not rule out liver fat. The clinician asks about weight and its change, activity, food pattern, sleep, conditions, medicines and relevant family history. Blood pressure, glycated haemoglobin or other glucose measures, lipids, platelets and the rest of the liver panel may also be reviewed according to the case, because a plan should address cardiovascular and general health alongside the liver [2, 3, 6].
Alcohol should be discussed honestly and without blame because the amount and pattern can change both interpretation and management. A full medicine and supplement list matters too; some products and herbs can injure the liver, but that is not a reason to stop prescribed treatment on your own. Bring each product's name and dose, and leave continuation or adjustment to the clinician who understands why it was prescribed. Viral hepatitis, autoimmune disease or a genetic cause may also need exclusion when the history or results point that way, but testing is selected individually rather than ordered as one fixed panel for everyone [3, 5, 9]. If your weight is within a typical range, read about fatty liver at normal weight.
What can you do now without a detox or crash diet?
Start with sustainable steps: reduce sugar-sweetened drinks and highly processed foods; build meals around vegetables, whole grains, suitable protein sources and unsaturated fats; and increase activity gradually within your medical ability. If you have excess weight, gradual loss can reduce liver fat, while greater improvement in inflammation and scarring usually needs more loss under suitable supervision. The aim is not a rapid number or starvation. Rapid loss and malnutrition can worsen liver health, and physical activity can still help even when the scale does not change as expected [7, 8].
Do not buy a “liver cleanse,” or start a vitamin, herb or internet medicine because of the scan. The word “natural” does not establish supplement safety, and some herbs can injure the liver or interact with treatment. Conversely, do not stop a medicine for diabetes, blood pressure or lipids simply because the report mentions fat; treating accompanying risks is central to care, and changes belong in a clinician review. The fatty-liver treatment and follow-up guide expands on lifestyle and monitoring without turning this page into a universal prescription. Your plan may differ with weight, glucose, fibrosis risk and medicines, so decisions should remain individual [1, 2, 7, 10].
When is follow-up due, and which signs should not wait?
There is no single schedule for everyone. Timing of repeat blood tests or fibrosis assessment depends on the first risk assessment, age, diabetes or other metabolic factors, and any change in symptoms or medicines. Some pathways repeat non-invasive assessment periodically when risk is low, while an indeterminate or higher result may need an earlier next step or referral. Agree with the clinician on the test name, timing and the change that would alter the plan. Copies of the scan and dated laboratory values are more useful than memory alone [1, 2, 4].
Uncomplicated fatty liver is usually not an emergency. New yellowing of the eyes or skin, dark urine with pale stool, rapid or marked swelling of the abdomen or legs, vomiting blood, black stool, confusion or unusual drowsiness, fainting, severe pain or persistent vomiting need urgent assessment according to severity. Do not wait for a routine follow-up or repeat scan if these appear. Without warning signs, arrange a structured review instead of collecting disconnected tests. An old normal result cannot explain a new symptom, while a fatty-liver report alone cannot prove the cause of every pain [6, 10].
Prepare for review and make the next step clear
Before the visit, bring the ultrasound report and images when available, all earlier liver, glucose, lipid and full-blood-count results, plus a list of medicines, supplements and doses. Briefly note weight change, blood pressure, glucose, alcohol use where relevant and new symptoms. Ask four practical questions: Does the appearance genuinely fit liver fat? Is another cause worth excluding? What is my fibrosis-risk assessment? When should we repeat a measure or change the plan? Those answers are more useful than trying to extract a fat percentage or final verdict from one sheet of paper [2, 3, 5].
If you need to connect the report with your history and examination and decide whether monitoring or further assessment is appropriate, you can request an appointment for fatty-liver assessment. In the clinic, decisions are based on the individual situation, without promising an outcome or ordering an extra test solely for reassurance. This page is educational and cannot replace an examination, particularly with pregnancy, acute illness, a new medicine or warning signs. The bottom line is that normal enzymes are reassuring about one defined part of the picture, while meaningful reassurance comes from assessing the cause, fibrosis risk and a follow-up plan you understand [1, 2, 5].
